|Articles|May 9, 2017
WIRB-Copernicus Acquires Again
WIRB-Copernicus Group (WCG) has announced the acquisition of MedAvante and ProPhase, and has named Dr. Jeffrey Litwin as CEO of the combined organization.
Advertisement
WIRB-Copernicus Group (WCG) has announced the acquisition of MedAvante and ProPhase, and has named Dr. Jeffrey Litwin as CEO of the combined organization. This acquisition provides WCG’s clients with a more comprehensive and integrated suite of study start-up solutions.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMGSeptember 15th 2025
Q&A: Strategies for Successful Global Clinical Trial DeliverySeptember 12th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
2
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
3
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
4
Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
